MR lymphography with a lymphotropic T1-type MR contrast agent: Gd-DTPA-PGM

Area of Science:

• Biomedical Imaging
• Radiochemistry
• Pharmacokinetics

Background:

• Lymph node imaging is crucial for diagnosing and staging diseases like cancer.
• Developing targeted contrast agents can improve the sensitivity and specificity of MR imaging for lymph nodes.

Purpose of the Study:

• To evaluate a novel paramagnetic lymphotropic MR contrast agent (Gd-DTPA-PGM) for T1-weighted MR imaging of lymph nodes.
• To determine optimal pharmacokinetic and imaging parameters for Gd-DTPA-PGM in preclinical models.
• To assess the potential of Gd-DTPA-PGM for detecting lymph node metastases.

Main Methods:

• Pharmacokinetic studies and MR imaging were performed in normal rats (n=88) and a rabbit model of lymph node metastases (n=8).
• Gd-DTPA-PGM was administered subcutaneously, and tissue accumulation, optimal dose (6-12 μmol Gd/kg), and timing (within 24 h) were determined.
• T1-weighted spoiled gradient echo sequences were used to evaluate lymph node signal-to-noise ratio (SNR) and tumor-lymph node contrast pre- and post-contrast administration.

Main Results:

• Maximum Gd-DTPA-PGM concentration in lymph nodes (popliteal, paraaortic) occurred within 24 hours post-subcutaneous injection.
• Highest lymph node SNR values and improved conspicuity of nodal metastases were achieved at 24 hours.
• Tumor-lymph node contrast significantly increased from 0.0±1.2 precontrast to 19.2±6.5 postcontrast.
• Gd-DTPA-PGM enhanced signal intensity in normal lymph nodes but not in metastatic ones.

Conclusions:

• Gd-DTPA-PGM demonstrates favorable lymph node accumulation and enhancement properties after subcutaneous administration.
• The agent shows potential for improving the detection of lymph node metastases using MR imaging.
• Further studies are warranted to explore its clinical utility in oncology.